Pharma company Biocon Limited disclosed a 56.8% year-on-year decrease in consolidated net profit to Rs 198.6 crore for the fourth quarter ending March 31, 2026. This decline was influenced by exceptional expenses related to various factors, including the implementation of the new labour code. Despite the profit drop, the company saw a revenue increase, with consolidated revenue rising to Rs 4,516.6 crore from Rs 4,417 crore in the same quarter last year.
Total expenses for the quarter climbed to Rs 4,241.2 crore compared to Rs 3,987.5 crore in the corresponding period of the previous financial year. Biocon mentioned that the quarter included an exceptional item outgo of Rs 80.4 crore under different categories, including the impact from the new labour code, affecting the company’s financial performance.
For the full financial year 2025-26, Biocon’s consolidated net profit sharply decreased to Rs 368.8 crore from Rs 1,429.4 crore in the previous fiscal year. However, the annual consolidated revenue from operations rose to Rs 16,927 crore from Rs 15,261.7 crore in the previous fiscal.
Commenting on the results, Kiran Mazumdar-Shaw highlighted that despite the challenging geopolitical environment, the company concluded FY26 on a positive note. She emphasized that the performance showcases the business’s resilience and disciplined execution throughout a crucial year of integration. Additionally, the company announced leadership changes, with Shreehas Tambe taking over as CEO and Managing Director from April 1, 2026, and Kedar Upadhye appointed as the Chief Financial Officer.
Biocon’s board proposed a final dividend of 50 paise per equity share with a face value of Rs 5 each for FY26, pending shareholders’ approval at the upcoming annual general meeting.
